$1.32 EPS Expected for ICON PLC (ICLR)

Wall Street await ICON PLC (NASDAQ:ICLR) to release earnings on October, 19. Analysts forecast earnings per share of $1.32, up exactly $0.13 or 10.92 % from 2014’s $1.19 EPS. The expected ICLR’s profit could reach $71.37 million giving the stock 21.09 P/E in the case that $1.32 earnings per share is reported. After posting $1.31 EPS for the previous quarter, ICON PLC’s analysts now forecast 0.76 % EPS growth. The stock decreased 0.22% or $0.25 on September 15, reaching $111.34. About 224,663 shares traded. ICON PLC (NASDAQ:ICLR) has risen 40.78% since September 18, 2016 and is uptrending. It has outperformed by 24.08% the S&P500.

ICON PLC (NASDAQ:ICLR) Ratings Coverage

Among 12 analysts covering Icon plc (NASDAQ:ICLR), 8 have Buy rating, 1 Sell and 3 Hold. Therefore 67% are positive. Icon plc had 22 analyst reports since July 29, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, June 8 by Robert W. Baird. The stock has “Buy” rating by Jefferies on Thursday, June 29. The company was downgraded on Thursday, June 9 by Avondale. On Friday, October 14 the stock rating was upgraded by Evercore to “Buy”. SunTrust downgraded the shares of ICLR in report on Friday, December 16 to “Hold” rating. The company was downgraded on Friday, December 16 by Suntrust Robinson. The firm has “Buy” rating by Robert W. Baird given on Thursday, August 31. The stock of ICON PLC (NASDAQ:ICLR) has “Hold” rating given on Friday, June 3 by Jefferies. The firm earned “Market Perform” rating on Wednesday, October 21 by Avondale. The stock of ICON PLC (NASDAQ:ICLR) earned “Buy” rating by SunTrust on Monday, July 31.

ICON public limited company is a contract research organization , which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company has market cap of $6.02 billion. The Firm is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies. It has a 22.6 P/E ratio. The Company’s services include clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics and laboratory services.

More news for ICON PLC (NASDAQ:ICLR) were recently published by: Seekingalpha.com, which released: “Icon PLC: A Hidden Gem In An Uncertain Industry” on August 29, 2017. Streetinsider.com‘s article titled: “BofA/Merrill Lynch Starts ICON plc (ICLR) at Buy” and published on September 11, 2017 is yet another important article.